The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: A new therapeutic approach

British Journal of Haematology

Volumn 166, Issue 2, 2014, Pages 177-188

  Sivina, Mariela ^a   Kreitman, Robert J ^b   Arons, Evgeny ^b   Ravandi, Farhad ^a   Burger, Jan A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B cell receptor; Bruton tyrosine kinase; Hairy cell leukaemia; Ibrutinib; Microenvironment

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; IBRUTINIB; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VERY ELDERLY;

B CELL RECEPTOR; BRUTON TYROSINE KINASE; HAIRY CELL LEUKAEMIA; IBRUTINIB; MICROENVIRONMENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84903692521     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12867     Document Type: Article

References (43)

1. Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., Kolibaba, K.S., Furman, R.R., Rodriguez, S., Chang, B.Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E. & Fowler, N.H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 88-94.
2. Arons, E., Suntum, T., Stetler-Stevenson, M. & Kreitman, R.J. (2009) VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood, 114, 4687-4695.
3. Burger, J.A. & Buggy, J.J. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI 32765). Leukemia & Lymphoma, 54, 2385-2391.
4. Burger, J.A. & Kipps, T.J. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107, 1761-1767.
5. Burger, J.A. & Montserrat, E. (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood, 121, 1501-1509.
6. Burger, J.A., Tsukada, N., Burger, M., Zvaifler, N.J., Dell'Aquila, M. & Kipps, T.J. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood, 96, 2655-2663.
7. Burger, J.A., Quiroga, M.P., Hartmann, E., Burkle, A., Wierda, W.G., Keating, M.J. & Rosenwald, A. (2009) High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood, 113, 3050-3058.
8. Burger, J.A., Sivina, M. & Ravandi, F. (2011) The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leukemia & Lymphoma, 52, 94-98.
9. Chiorazzi, N. & Efremov, D.G. (2013) Chronic lymphocytic leukemia: a tale of one or two signals? Cell Research, 23, 182-185.
10. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
11. Dietrich, S., Hullein, J., Hundemer, M., Lehners, N., Meissner, J., Jethwa, A., Acker, T., Galanov, B., Andrulis, M., Schulte, C., Mandel, T., Dreger, P., Frohling, S., von Kalle, C., Ho, A.D., Glimm, H. & Zenz, T. (2012) Exquisite sensitivity of refractory hairy-cell leukemia to BRAF inhibition with Vemurafenib. Onkologie, 35, 246-247.
12. Durig, J., Schmucker, U. & Duhrsen, U. (2001) Differential expression of chemokine receptors in B cell malignancies. Leukemia, 15, 752-756.
13. Else, M., Dearden, C.E., Matutes, E., Garcia-Talavera, J., Rohatiner, A.Z., Johnson, S.A., O'Connor, N.T., Haynes, A., Osuji, N., Forconi, F., Lauria, F. & Catovsky, D. (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. British Journal of Haematology, 145, 733-740.
14. Forconi, F. (2011) Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematological Oncology, 29, 55-66.
15. Forconi, F., Raspadori, D., Lenoci, M. & Lauria, F. (2005) Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica, 90, 266-268.
16. Forconi, F., Sozzi, E., Rossi, D., Sahota, S.S., Amato, T., Raspadori, D., Trentin, L., Leoncini, L., Gaidano, G. & Lauria, F. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Hematologica, 93, 697-705.
17. Forconi, F., Cencini, E., Sicuranza, A., Sozzi, E. & Lauria, F. (2011) Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. Leukemia & Lymphoma, 52, 15-23.
18. Friedberg, J.W., Sharman, J., Sweetenham, J., Johnston, P.B., Vose, J.M., Lacasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J.P., Cripe, L.D., Gregory, S.A., Sterba, M.P., Lowe, A.M., Levy, R. & Shipp, M.A. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 115, 2578-2585.
19. Furman, R.R., Byrd, J.C., Brown, J.R., Coutre, S.E., Benson, D.M. Jr, Wagner-Johnston, N.D., Flinn, I.W., Kahl, B.S., Spurgeon, S.E., Lannutti, B., Giese, N.A., Webb, H.K., Ulrich, R.G., Peterman, S., Holes, L.M. & Yu, A.S. (2010) CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood, 116, 31a.
20. Ghiotto, F., Fais, F., Valetto, A., Albesiano, E., Hashimoto, S., Dono, M., Ikematsu, H., Allen, S.L., Kolitz, J., Rai, K.R., Nardini, M., Tramontano, A., Ferrarini, M. & Chiorazzi, N. (2004) Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. Journal of Clinical Investigation, 113, 1008-1016.
21. de Gorter, D.J., Beuling, E.A., Kersseboom, R., Middendorp, S., van Gils, J.M., Hendriks, R.W., Pals, S.T. & Spaargaren, M. (2007) Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity, 26, 93-104.
22. Herman, S.E., Gordon, A.L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K.A., Buggy, J.J., Hamdy, A., Johnson, A.J. & Byrd, J.C. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117, 6287-6296.
23. Hoellenriegel, J., Meadows, S.A., Sivina, M., Wierda, W.G., Kantarjian, H., Keating, M.J., Giese, N., O'Brien, S., Yu, A., Miller, L.L., Lannutti, B.J. & Burger, J.A. (2011) The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood, 118, 3603-3612.
24. Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075-13080.
25. Kuppers, R. (2005) Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews Cancer, 5, 251-262.
26. LeBien, T.W. & Tedder, T.F. (2008) B lymphocytes: how they develop and function. Blood, 112, 1570-1580.
27. Matutes, E. (2006) Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematology-Oncology Clinics of North America, 20, 1051-1063.
28. Messmer, B.T., Albesiano, E., Efremov, D.G., Ghiotto, F., Allen, S.L., Kolitz, J., Foa, R., Damle, R.N., Fais, F., Messmer, D., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (2004) Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. Journal of Experimental Medicine, 200, 519-525.
29. Ponader, S., Chen, S.S., Buggy, J.J., Balakrishnan, K., Gandhi, V., Wierda, W.G., Keating, M.J., O'Brien, S., Chiorazzi, N. & Burger, J.A. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119, 1182-1189.
30. Quiroga, M.P., Balakrishnan, K., Kurtova, A.V., Sivina, M., Keating, M.J., Wierda, W.G., Gandhi, V. & Burger, J.A. (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood, 114, 1029-1037.
31. Ravandi, F., O'Brien, S., Jorgensen, J., Pierce, S., Faderl, S., Ferrajoli, A., Koller, C., Challagundla, P., York, S., Brandt, M., Luthra, R., Burger, J., Thomas, D., Keating, M. & Kantarjian, H. (2011) Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood, 118, 3818-3823.
32. Robak, T. (2011) Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treatment Reviews, 37, 3-10.
33. de Rooij, M.F., Kuil, A., Geest, C.R., Eldering, E., Chang, B.Y., Buggy, J.J., Pals, S.T. & Spaargaren, M. (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 119, 2590-2594.
34. Siegel, R., Naishadham, D. & Jemal, A. (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29.
35. Sivina, M., Hartmann, E., Kipps, T.J., Rassenti, L., Krupnik, D., Lerner, S., Lapushin, R., Xiao, L., Huang, X., Werner, L., Neuberg, D., Kantarjian, H., O'Brien, S., Wierda, W.G., Keating, M.J., Rosenwald, A. & Burger, J.A. (2011) CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood, 117, 1662-1669.
36. Spaargaren, M., Beuling, E.A., Rurup, M.L., Meijer, H.P., Klok, M.D., Middendorp, S., Hendriks, R.W. & Pals, S.T. (2003) The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. Journal of Experimental Medicine, 198, 1539-1550.
37. Swerdlow, S., Campo, E. & Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer, Lyon, France.
38. Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M.P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V.A., Sportoletti, P., Pettirossi, V., Mannucci, R., Elliott, O., Liso, A., Ambrosetti, A., Pulsoni, A., Forconi, F., Trentin, L., Semenzato, G., Inghirami, G., Capponi, M., Di Raimondo, F., Patti, C., Arcaini, L., Musto, P., Pileri, S., Haferlach, C., Schnittger, S., Pizzolo, G., Foa, R., Farinelli, L., Haferlach, T., Pasqualucci, L., Rabadan, R. & Falini, B. (2011) BRAF mutations in hairy-cell leukemia. New England Journal of Medicine, 364, 2305-2315.
39. Tobin, G., Thunberg, U., Johnson, A., Eriksson, I., Soderberg, O., Karlsson, K., Merup, M., Juliusson, G., Vilpo, J., Enblad, G., Sundstrom, C., Roos, G. & Rosenquist, R. (2003) Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood, 101, 4952-4957.
40. Weston-Bell, N.J., Hendriks, D., Sugiyarto, G., Bos, N.A., Kluin-Nelemans, H.C., Forconi, F. & Sahota, S.S. (2013) Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia, 27, 241-245.
41. Widhopf, G.F. 2nd, Rassenti, L.Z., Toy, T.L., Gribben, J.G., Wierda, W.G. & Kipps, T.J. (2004) Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood, 104, 2499-2504.
42. Wong, S. & Fulcher, D. (2004) Chemokine receptor expression in B-cell lymphoproliferative disorders. Leukemia & Lymphoma, 45, 2491-2496.
43. Xi, L., Arons, E., Navarro, W., Calvo, K.R., Stetler-Stevenson, M., Raffeld, M. & Kreitman, R.J. (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood, 119, 3330-3332.